Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 20/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.69 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.69 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5627677 | 0.94 | PTGER1 (0.70) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5630713 | 0.92 | PTGER1 (0.78) | PTGER1CYP2C9 | |
| SCHEMBL5630282 | 0.91 | PTGER1 (0.66) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5628108 | 0.90 | PTGER1 (0.65) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5628896 | 0.90 | PTGER1 (0.68) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5629747 | 0.89 | PTGER1 (0.77) | PTGER1CYP2C9 | |
| SCHEMBL5629324 | 0.89 | PTGER1 (0.65) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5629969 | 0.89 | PTGER1 (0.67) | PTGER1CYP2C9 | |
| SCHEMBL5627541 | 0.89 | PTGER1 (0.83) | PTGER1TBXA2RPTGER4PTGER3CYP2C9 | |
| SCHEMBL5629197 | 0.89 | PTGER1 (0.81) | PTGER1TBXA2RPTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| EP-1509499-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101959-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | PTGER1, PTGDR, PTGIR | PTGER1 1/4885TBXA2R 16/4885PTGER4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.